{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Allen-Philbey K"],"pubmed_abstract":["<h4>Objective</h4>To report on safety and effectiveness of subcutaneous cladribine (Litak<sup>®</sup>) in multiple sclerosis (MS) patients.<h4>Methods</h4>Litak<sup>®</sup> was offered to MS-patients irrespective of disease course. Litak<sup>®</sup> 10 mg was administered for 3-4 days during week 1. Based on lymphocyte count at week 4, patients received another 0-3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts.<h4>Results</h4>In all, 208 patients received at least "],"journal":["Therapeutic advances in neurological disorders"],"pagination":["17562864211057661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8842147"],"repository":["biostudies-literature"],"pubmed_title":["Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients."],"pmcid":["PMC8842147"],"pubmed_authors":["Giovannoni G","Constantinescu CS","Mattoscio M","Pavitt S","MacDougall A","Gran B","Ford H","Dalton C","Baker D","Blain C","Stennett A","Webb S","Juliusson G","Marta M","Sharrack B","Mao Z","Khaleeli Z","Peruzzotti-Jametti L","Alvarez-Gonzalez C","Chapman C","Adams A","Bianchi L","Chung K","Farrell RA","De Trane S","Fisniku L","Zhou X","Schmierer K","Silber E","Turner BP","Mathews J","Scalfari A","Tallantyre EC","Gnanapavan S","Yildiz O","Hobart J","Pearson O","Allen-Philbey K"],"additional_accession":[]},"is_claimable":false,"name":"Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.","description":"<h4>Objective</h4>To report on safety and effectiveness of subcutaneous cladribine (Litak<sup>®</sup>) in multiple sclerosis (MS) patients.<h4>Methods</h4>Litak<sup>®</sup> was offered to MS-patients irrespective of disease course. Litak<sup>®</sup> 10 mg was administered for 3-4 days during week 1. Based on lymphocyte count at week 4, patients received another 0-3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts.<h4>Results</h4>In all, 208 patients received at least ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-06-01T02:33:10.949Z","creation":"2025-06-01T02:33:10.949Z"},"accession":"S-EPMC8842147","cross_references":{"pubmed":["35173808"],"doi":["10.1177/17562864211057661"]}}